400 Summit Drive
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
CEO: Udit Batra
72 articles with MilliporeSigma
One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-BioNTech Covid-19 Vaccine
MilliporeSigma Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies
MilliporeSigma will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Adds to MilliporeSigma's lipid manufacturing expertise, providing an integrated offering across mRNA value chain
MilliporeSigma announced the broadening of its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.
MilliporeSigma inaugurated a new $14.4 million industrial water treatment plant at its Jaffrey, New Hampshire, location.
In 1996, Udit Batra received his Ph.D. in chemical engineering from Princeton University. 24 years later, he heads a MilliporeSigma, $7.5 billion global life sciences company with a catalog of some 300,000 items used by life sciences researchers and developers throughout the world.
ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization
Feb. 10, 2020 12:30 UTC WOBURN, Mass.--( BUSINESS WIRE )-- ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Under the agreement,
MilliporeSigma Acquires Data Management and Analysis Platform for Biopharma Real-Time Process Monitoring and Reporting
MilliporeSigma has acquired all ownership rights to the ProcessPad™ platform from Simplyfeye Softwares Private Limited. The agreement includes the transfer of all copyrights and relevant intellectual property related to this software platform.
MilliporeSigma announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative.
New bio-derived product is a safer, more sustainable alternative for Dimethylformamide and N-Methyl-2-pyrrolidone solvents
Molsheim, France center supports pharmaceutical and biotechnology customers from pre-clinical through full-scale production in non-GMP environment
MilliporeSigma to Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China
MilliporeSigma announced the signing of a non-binding Memorandum of Understanding with GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research
MilliporeSigma, a subsidiary of Merck KGaA, Darmstadt, Germany, handed out $30,000 to three graduate students for their research projects.
MilliporeSigma’s New BioReliance® Rapid Sterility Testing Service Delivers Results in Half the Time as Traditional Methods
MilliporeSigma has launched its sterility testing service for a direct inoculation method using the BACT/Alert® 3D Rapid Microbial Detection System.
Quartzy, the only free online laboratory supply management and ordering platform, announced today its partnership with South Elgin-based BioBlaze Community Bio Lab to provide the non-profit’s scientists with access to competitive terms on laboratory supplies and enhanced support tailored to their emergent scientific endeavors.
MilliporeSigma’s BioReliance® Product Characterization Services Help Ensure Purity, Safety and Efficacy
MilliporeSigma has launched its BioReliance® Product Characterization Portfolio of tests for quality assessment of biologic drugs.
MilliporeSigma announced that the Korean Intellectual Property Office and the Israel Patent Office have each granted patent applications for the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.
MilliporeSigma Launches Viresolve Barrier Capsule Filters to Protect Against Bioreactor Contamination
MilliporeSigma today introduced Viresolve Barrier capsule filters to reduce the risk of bioreactor contamination.
BioLife Solutions today announced that it has executed an OEM agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under private label to MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.